



University of Groningen

Digital adherence technologies in tuberculosis

Hafez, Gaye; van Boven, Job F M

Published in: The Lancet Global Health

DOI: 10.1016/S2214-109X(23)00308-X

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2023

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Hafez, G., & van Boven, J. F. M. (2023). Digital adherence technologies in tuberculosis. *The Lancet Global Health*, *11*(9), e1341-e1342. https://doi.org/10.1016/S2214-109X(23)00308-X

Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

oa

Digital adherence technologies in tuberculosis

With great interest, we read the clusterrandomised superiority trial by Xiaoqiu Liu and colleagues¹ published in The Lancet Global Health. The authors should be applauded for providing this large and important study investigating the use of digital adherence technology to support tuberculosis treatment. However, although adherence rates were slightly improved in the intervention group, no effect on the primary composite outcome of death, loss to follow-up or stopping treatment, treatment failure, switch to multidrugresistant tuberculosis treatment, or tuberculosis recurrence by 18 months from treatment start was shown.

Previous research has shown an association between non-adherence to treatment and poor tuberculosis outcomes.² As such, the planned adherence interventions in this

trial might not have been optimally implemented or adapted to the needs of the patient. First, the shared decision-making approach, one of the adherence-enhancing strategies that has been shown to be effective in other fields (eq. asthma),³ was not implemented as initially planned; in some regions there was more clinician decision making instead. Second, the authors speculate that "certain patterns of non-adherence are associated with increased risk of poor treatment outcomes or treatment recurrence".1 Digital adherence technologies could show these patterns in close to real time. However, we would like to note that patterns of digital data do not show everything. Beyond looking at data patterns, much more emphasis is needed on the actual underlying reasons for those suboptimal patterns and on providing personalised support to patients.

WHO distinguishes between five different dimensions of treatment adherence: socioeconomic factors,

Socioeconomic factors Family support, family or caregiver factors, social support, stigma of a disease, costs of drugs or treatment, prescription coverage, socioeconomic status, and employment status Health-care team and system-related factors Barriers to health care, drug supply, prescriptions from specialists, information about drug administration*, health-care team and patient communication and relationship*, and follow-up Condition-related factors **Five dimensions** Presence of symptoms, disease severity, clinical improvement, 3 psychiatric condition, specific diagnoses or indications, and of adherence duration of the disease Therapy-related factors Adverse effects, tolerability of the regimen, drug effectiveness, duration of treatment, drug type, and well organised treatment Patient-related factors Age, gender, marital status, education*, ethnicity, housing, cognitive function, forgetfulness and reminders*, knowledge*, health beliefs (eg, motivation)*, psychological profile, comorbidities and patient history, alcohol or substance abuse, and patient-related barriers to compliance

Figure: Five dimensions of treatment adherence and determinants that can be managed digitally *Can be managed digitally. health-system factors, conditionrelated factors, therapy-related factors, and patient-related non-adherence factors (figure).⁴ Each of these factors requires different adherenceenhancing strategies.⁵ For example, digital tools can be used as reminders and for providing motivational messages, but other non-adherence factors (eq, overcoming side-effects or fear of side-effects, financial constraints, or lack of knowledge) still require an intervention provided in person, possibly supported by digital data. Current digital data profiling should not merely be used as an independent solution that is the same for everyone. Instead, it should be used to facilitate shared decision making and support personalised interventions for tuberculosis treatment.

Importantly, in the trial by Liu and colleagues,¹ many doctors did not know how to manage digital adherence data. Therefore, training clinicians on how to interpret digital data decision-support tools is needed. The combination of digital data and behavioural phenotyping requires structured questions and data collection that could be integrated into digital tools. As such, tuberculosis treatment could change from being the same for everyone to being adapted to individual patients.²

This Correspondence was an outcome of a short-term scientific mission in the University Medical Center Groningen (University of Groningen, Groningen, Netherlands) in April, 2023. GH has received a grant from COST Action CA19132 ENABLE, supported by the European Cooperation in Science and Technology (COST). JFMvB has received grants and consultancy fees, paid to his insitution, from multiple manufacturers of digital adherence technologies but that are unrelated to this Correspondence.

Copyright @ 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

*Gaye Hafez, Job F M van Boven gaye.hafez@altinbas.edu.tr

Department of Pharmacology, Faculty of Pharmacy, Altinbas University, Istanbul 34140, Türkiye (GH); Department of Clinical Pharmacy and Pharmacology, Medication Adherence Expertise Center of the Northern Netherlands, University Medical Center Groningen, University of Groningen, Groningen, Netherlands (JFMVB)

Downloaded for Anonymous User (n/a) at University of Groningen from ClinicalKey.com by Elsevier on August 29, 2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.

- Liu X, Thompson J, Dong H, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. *Lancet Glob Health* 2023; **11**: e693–703.
- 2 Chimeh RA, Gafar F, Pradipta IS, et al. Clinical and economic impact of medication nonadherence in drug-susceptible tuberculosis: a systematic review. Int J Tuberc Lung Dis 2020; 24: 811–19.
- 3 Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010; 181: 566–77.
- 4 WHO. Adherence to long-term therapies: evidence for action. 2003. https://apps.who. int/iris/handle/10665/42682 (accessed July 19, 2023).
- 5 Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol 2013; 4: 91.